10x Genomics (TXG) and The Competition Head-To-Head Review

Share on StockTwits

10x Genomics (NASDAQ: TXG) is one of 29 publicly-traded companies in the “Analytical instruments” industry, but how does it weigh in compared to its rivals? We will compare 10x Genomics to related companies based on the strength of its earnings, dividends, analyst recommendations, valuation, institutional ownership, risk and profitability.

Profitability

This table compares 10x Genomics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
10x Genomics -31.06% -19.18% -13.01%
10x Genomics Competitors -145.99% -429.38% -25.75%

Institutional & Insider Ownership

60.8% of 10x Genomics shares are held by institutional investors. Comparatively, 57.8% of shares of all “Analytical instruments” companies are held by institutional investors. 13.3% of 10x Genomics shares are held by company insiders. Comparatively, 13.3% of shares of all “Analytical instruments” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares 10x Genomics and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
10x Genomics $245.89 million -$31.25 million -174.65
10x Genomics Competitors $1.07 billion $262.33 million 10.97

10x Genomics’ rivals have higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of current ratings and target prices for 10x Genomics and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
10x Genomics 0 0 1 0 3.00
10x Genomics Competitors 314 1245 1597 81 2.45

10x Genomics presently has a consensus price target of $145.00, indicating a potential upside of 3.78%. As a group, “Analytical instruments” companies have a potential downside of 12.19%. Given 10x Genomics’ stronger consensus rating and higher probable upside, research analysts plainly believe 10x Genomics is more favorable than its rivals.

Summary

10x Genomics beats its rivals on 7 of the 12 factors compared.

10x Genomics Company Profile

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. Its company offers chromium instruments, enzymes, microfluidic chips, slides, reagents, and other consumable products. The company's single cell solution runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics, including the physical organization of DNA; single cell CNV for measuring cellular heterogeneity through DNA changes, such as copy number variation; and visium spatial gene expression solution that measures the spatial gene expression patterns across a tissue sample. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10X Genomics, Inc. in November 2014. 10x Genomics, Inc. was founded in 2012 and is headquartered in Pleasanton, California.

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

National Asset Management Inc. Has $545,000 Stock Holdings in Booking Holdings Inc.
National Asset Management Inc. Has $545,000 Stock Holdings in Booking Holdings Inc.
Critical Review: ClearSign Technologies  versus Its Rivals
Critical Review: ClearSign Technologies versus Its Rivals
National Asset Management Inc. Has $518,000 Stock Holdings in First Trust Senior Floating Rate Income Fund II
National Asset Management Inc. Has $518,000 Stock Holdings in First Trust Senior Floating Rate Income Fund II
ClariVest Asset Management LLC Sells 248,317 Shares of Micron Technology, Inc.
ClariVest Asset Management LLC Sells 248,317 Shares of Micron Technology, Inc.
National Asset Management Inc. Purchases 116 Shares of Xilinx, Inc.
National Asset Management Inc. Purchases 116 Shares of Xilinx, Inc.
10x Genomics  and The Competition Head-To-Head Review
10x Genomics and The Competition Head-To-Head Review


 
© 2006-2020 Zolmax.